IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma

Status unconfirmed · Phase 1

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: IL-4(38-37)-PE38KDEL immunotoxin may locate tumor cells and kill them without harming normal cells. This may be an effective treatment for recurrent malignant astrocytoma. PURPOSE: Phase I trial to study the effectiveness of IL-4(38-37)-PE38KDEL immunotoxin in treating patients who have recurrent malignant astrocytoma.

Key facts

Study ID

NCT00003842

Run by

Barrett Cancer Center

People needed

30

Starts

1999-03-01

Last updated by the study team

2013-12-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Southern California, Healthcare Consultation Center — Los Angeles, California, United States
• UCSF Cancer Center and Cancer Research Institute — San Francisco, California, United States
• Neuro-Oncology Service — San Francisco, California, United States
• John Wayne Cancer Institute — Santa Monica, California, United States
• Laboratory of Molecular Biology — Bethesda, Maryland, United States
• Food and Drug Administration — Rockville, Maryland, United States
• St. Louis University Health Sciences Center — St Louis, Missouri, United States
• Herbert Irving Comprehensive Cancer Center — New York, New York, United States
• Charlotte Neurosurgical Associates — Charlotte, North Carolina, United States
• Barrett Cancer Center, The University Hospital — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.